摘要
目的:分析罗沙司他联合左卡尼汀治疗维持性血液透析伴肾性贫血临床疗效及残余肾功能的影响。方法:选取2022年6月至2023年6月我院收治的80例维持性血液透析伴肾性贫血患者,根据治疗的不同分为对照组(采用罗沙司他胶囊治疗)和观察组(采用罗沙司他胶囊联合左卡尼汀治疗),每组40例。治疗8 w后采用全自动血液分析仪检测贫血指标,如红细胞计数(Red blood cell,RBC)、血红蛋白(Hemoglobin,Hb)、红细胞积压(Hematocrit,Hct)水平以及肾功能指标,包括血尿素氮(Blood urea nitrogen,BUN)、血肌酐(Serum Creatinine,SCr)、24 h尿蛋白排泄率(24 h Urinary protein,24hUPE)水平;采用酶联免疫法检测铁代谢指标:血清铁蛋白(Serum Ferritin,SF)、转铁蛋白饱和度(Transferrin saturation,TSAT)、血清转铁蛋白受体(Serum transferrin receptor,STFR)水平;并血压计检测舒张压以及收缩压。结果:观察组(97.50%)的总有效率高于对照组(85.00%)(P<0.05);两组治疗8 w后RBC、Hb、Hct、SF、TSAT、STAT水平及24 h尿量均升高,BUN、SCr、24hUPE水平以及血压波动均降低;且观察组均比对照组更为显著(P<0.05);观察组(7.50%)不良反应发生率低于对照组(15.00%),但无统计学差异(P>0.05)。结论:罗沙司他结合左卡尼汀维持性血液透析伴肾性贫血可减轻临床症状,改善患者贫血及肾功能相关指标,用药安全可靠。
Objective:To analyze the clinical efficacy and residual renal function of Roxallistat combined with L-carnitine in the treatment of maintenance hemodialysis with renal anemia.Methods:80 patients with maintenance hemodialysis with renal anemia admitted to our hospital from June 2022 to June 2023 were selected and divided into control group(treated with Rosallistat capsule)and observation group(treated with Rosallistat capsule combined with L-carnitine)according to different treatments,with 40 cases in each group.After 8 w of treatment,anemia indexes,such as Red blood cell(RBC),Hemoglobin(Hb),Hematocrit(Hct)level,and renal function indexes,were detected by automatic blood analyzer.Including Blood urea nitrogen(BUN),Serum Creatinine(SCr),24h Urinary protein excretion rate(24hUPE)level.Enzyme-linked immunoassay was used to detect iron metabolism indexes:Serum Ferritin(SF),Transferrin saturation(TSAT),Serum transferrin receptor(STFR)levels;Diastolic and systolic blood pressure were measured by a sphygmomanometer.Results:The total effective rate of observation group(97.50%)was higher than that of control group(85.00%)(P<0.05).After 8 w of treatment,RBC,Hb,Hct,SF,TSAT,STAT levels and 24h urine volume were increased,BUN,SCr,24hUPE levels and blood pressure fluctuation were decreased in both groups.The observation group was more significant than the control group(P<0.05).The incidence of adverse reactions in observation group(7.50%)was lower than that in control group(15.00%),but there was no statistical difference(P>0.05).Conclusion:Roxallistat combined with L-carnitine maintenance hemodialysis with renal anemia can alleviate clinical symptoms,improve anemia and renal function related indexes,and the drug is safe and reliable.
作者
罗娟
邹芳琴
郑婕
李小生
Luo Juan;Zou Fang-qin;Zheng Jie-sheng;Li Xiao-sheng(Department of Nephrology,The First Affiliated Hospital of Gannan Medical College,Ganzhou 341000,Jiangxi,China)
出处
《四川生理科学杂志》
2024年第1期19-21,共3页
Sichuan Journal of Physiological Sciences
基金
赣州市指导性科技计划(编号:20222ZDX8577)。
